RT Journal Article
SR Electronic
T1 A novel variant of interest of SARS-CoV-2 with multiple spike mutations detected through travel surveillance in Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.30.21254323
DO 10.1101/2021.03.30.21254323
A1 de Oliveira, Tulio
A1 Lutucuta, Silvia
A1 Nkengasong, John
A1 Morais, Joana
A1 Paixão, Joana Paula
A1 Neto, Zoraima
A1 Afonso, Pedro
A1 Miranda, Julio
A1 David, Kumbelembe
A1 Inglês, Luzia
A1 Raisa Rivas Carralero, Amilton Pereira Agostinho Paulo
A1 Freitas, Helga Reis
A1 Mufinda, Franco
A1 Tessema, Sofonias Kifle
A1 Tegally, Houriiyah
A1 San, Emmanuel James
A1 Wilkinson, Eduan
A1 Giandhari, Jennifer
A1 Pillay, Sureshnee
A1 Giovanetti, Marta
A1 Naidoo, Yeshnee
A1 Katzourakis, Aris
A1 Ghafari, Mahan
A1 Singh, Lavanya
A1 Tshiabuila, Derek
A1 Martin, Darren
A1 Lessells, Richard J
YR 2021
UL http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254323.abstract
AB At the end of 2020, the Network for Genomic Surveillance in South Africa (NGS-SA) detected a SARS-CoV-2 variant of concern (VOC) in South Africa (501Y.V2 or PANGO lineage B.1.351)1. 501Y.V2 is associated with increased transmissibility and resistance to neutralizing antibodies elicited by natural infection and vaccination2,3. 501Y.V2 has since spread to over 50 countries around the world and has contributed to a significant resurgence of the epidemic in southern Africa. In order to rapidly characterize the spread of this and other emerging VOCs and variants of interest (VOIs), NGS-SA partnered with the Africa Centres for Disease Control and Prevention and the African Society of Laboratory Medicine through the Africa Pathogen Genomics Initiative to strengthen SARS-CoV-2 genomic surveillance across the region.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for genomics surveillance was provided by the South African Medical Research Council (SAMRC), the South African Department of Science and Innovation (DSI), the Africa Centres for Disease Control and Prevention (Africa CDC) and the African Society of Laboratory Medicine (ASLM) through the Africa Pathogen Genomics Initiative (Africa PGI)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:he project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee. Protocol reference number: BREC/00001195/2020. Project title: COVID-19 transmission and natural history in KwaZulu-Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care. Patient consent was not required for the genomic surveillance. This requirement was waived by the Research Ethics Committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the sequences are available at GISAID. All of the short reads are available at the Short Read Archive (SRA) of the National Centre for Biotechnology Information (NCBI) (Bioproject Accession: PRJNA717113). https://www.krisp.org.za